Aurobindo Pharma Limited Website

Aurobindo Pharma Limited

NSEI-AUROPHARMA

Income Statement
Mar '15
Mar '16
Mar '17
Mar '18
Mar '19
Mar '20
Mar '21
Mar '22
Mar '23
Mar '24
LTM

Operating Revenues

230,985.1

247,746.2

234,554.9

248,553.8

290,018.7

296,688.8

Other Revenues, Total

—

—

—

—

—

—

—

494.9

Total Revenues

230,985.1

247,746.2

234,554.9

248,553.8

290,018.7

297,183.7

Total Revenues % Chg.

18.1%

7.3%

-5.3%

6%

16.7%

16.7%

Cost of Goods Sold, Total

100,285.8

101,897.7

104,498.8

116,416.7

129,856.9

129,036.6

Gross Profit

130,699.3

145,848.5

130,056.1

132,137.1

160,161.8

168,147.1

Selling General & Admin Expenses, Total

33,332.9

36,575.6

35,751.1

36,560.1

40,433.6

41,633.4

Depreciation & Amortization

9,667.1

10,553.9

11,265.2

12,375.5

14,919.1

15,695.3

Other Operating Expenses

48,298.4

54,183.3

49,975.5

58,082.6

60,894

62,997.5

Other Operating Expenses, Total

91,298.4

101,312.8

96,991.8

107,018.2

116,246.7

120,326.2

Operating Income

39,400.9

44,535.7

33,064.3

25,118.9

43,915.1

47,820.9

Interest Expense, Total

-2,870

-595.7

-368.4

-1,289.5

-2,680.9

-3,225.8

Interest And Investment Income

209.1

223.7

349.7

1,485.2

2,883

2,883

Net Interest Expenses

-2,660.9

-372

-18.7

195.7

202.1

-342.8

Income (Loss) On Equity Invest.

—

-151.7

-553.6

-312.5

-116.7

-171.6

-157.4

Currency Exchange Gains (Loss)

1,056.7

1,035.8

699.6

—

387.8

21

Other Non Operating Income (Expenses)

153.9

1,521.4

1,028.2

974.6

1,672.4

3,085.2

EBT, Excl. Unusual Items

37,798.9

46,167.3

34,460.9

26,172.5

46,005.8

50,426.9

Restructuring Charges

—

—

—

—

—

—

—

—

—

-986.6

-289.1

Merger & Related Restructuring Charges

—

—

—

—

—

—

—

—

—

—

Impairment of Goodwill

—

—

—

—

—

—

-4,349.2

—

-70.3

-27.4

-27.4

Gain (Loss) On Sale Of Investments

—

—

—

—

—

290.8

—

1

1

Gain (Loss) On Sale Of Assets

-370.4

-1,411.2

-400.2

132.3

234.9

234.9

Asset Writedown

—

—

—

—

—

—

—

-1,922.2

-239.6

-2,834.3

-2,834.3

Other Unusual Items

—

—

—

1.9

33,029

1,298.1

130.1

1,406.5

1,406.5

EBT, Incl. Unusual Items

37,430.4

73,435.9

33,727.4

26,125

43,799.9

48,918.5

Income Tax Expense

8,993.5

20,097.7

7,256.3

6,848.5

12,110.2

13,743.7

Earnings From Continuing Operations

28,436.9

53,338.2

26,471.1

19,276.5

31,689.7

35,174.8

Minority Interest

14.5

10.2

10.4

-1.5

40

39.6

Net Income

28,451.4

53,348.4

26,481.5

19,275

31,729.7

35,214.4

Preferred Dividend and Other Adjustments

—

—

—

—

—

0.1

—

—

—

—

—

Net Income to Common Incl Extra Items

28,451.3

53,348.4

26,481.5

19,275

31,729.7

35,214.4

Net Income to Common Excl. Extra Items

28,451.3

53,348.4

26,481.5

19,275

31,729.7

35,214.4

Total Shares Outstanding

585.9

585.9

585.9

585.9

585.9

585.9

Weighted Avg. Shares Outstanding

585.9

585.9

585.9

585.9

585.9

585.9

Weighted Avg. Shares Outstanding Dil

585.9

585.9

585.9

585.9

585.9

585.9

EPS

48.6

91

45.2

32.9

54.2

60.1

EPS Diluted

48.6

91

45.2

32.9

54.2

60.1

EBITDA

48,017.4

53,947.1

43,114.2

36,344.1

57,641.2

62,172.2

Effective Tax Rate

24%

27.4%

21.5%

26.2%

27.6%

28.1%